Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance-Reference-Cited by-同舟云学术

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance

Published:2023-11-10 Issue:11 Volume:12 Page:1612
ISSN:2079-6382
Container-title:Antibiotics
language:en
Short-container-title:Antibiotics

Author:

Duda-Madej Anna¹^ORCID,Viscardi Szymon²^ORCID,Topola Ewa²^ORCID

Affiliation:

1. Department of Microbiology, Faculty of Medicine, Wroclaw Medical University, Chałubińskiego 4, 50-368 Wrocław, Poland

2. Faculty of Medicine, Wroclaw Medical University, Ludwika Pasteura 1, 50-367 Wrocław, Poland

Abstract

Due to the fact that there is a steadily increasing trend in the area of antimicrobial resistance in microorganisms, there is a need to look for new treatment alternatives. One of them is the search for new β-lactamase inhibitors and combining them with β-lactam antibiotics, with the aim of increasing the low-dose efficacy, as well as lowering the resistance potential of bacterial strains. This review presents the positive effect of meropenem in combination with a vaborbactam (MER-VAB). This latest antibiotic-inhibitor combination has found particular use in the treatment of infections with the etiology of carbapenem-resistant Enterobacterales (CRE), Gram-negative bacteria, with a high degree of resistance to available antimicrobial drugs.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology

Link

https://www.mdpi.com/2079-6382/12/11/1612/pdf

Reference74 articles.

1. The WHO AWaRe (Access, Watch, Reserve) Antibiotic Book and Prevention of Antimicrobial Resistance;Zanichelli;Bull. World Health Organ.,2023

2. (2018). WHO Report on Surveillance of Antibiotic Consumption: 2016–2018 Early Implementation, World Health Organization.

3. Global Increase and Geographic Convergence in Antibiotic Consumption between 2000 and 2015;Klein;Proc. Natl. Acad. Sci. USA,2018

4. Global Antibiotic Consumption and Usage in Humans, 2000–18: A Spatial Modelling Study;Browne;Lancet Planet. Health,2021

5. Al Sulayyim, H.J., Ismail, R., Al Hamid, A., and Ghafar, N.A. (2022). Antibiotic Resistance during COVID-19: A Systematic Review. Int. J. Environ. Res. Public Health, 19.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia;Antibiotics;2024-07-05

2. The potential of EGCG in modulating the oral-gut axis microbiota for treating inflammatory bowel disease;Phytomedicine;2024-07

3. Tackling Carbapenem Resistance and the Imperative for One Health Strategies—Insights from the Portuguese Perspective;Antibiotics;2024-06-14

4. Novel Siderophore Cephalosporin and Combinations of Cephalosporins with β-Lactamase Inhibitors as an Advancement in Treatment of Ventilator-Associated Pneumonia;Antibiotics;2024-05-14

5. Antimicrobial Peptides towards Clinical Application—A Long History to Be Concluded;International Journal of Molecular Sciences;2024-04-29